- Investing.com
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Autoimmune Pivot | IGM Biosciences shifts focus to autoimmune diseases, streamlining its pipeline and preserving capital for key development programs in a growing market |
Imvotamab's Potential | Explore the promise of IGM's lead candidate in treating rheumatoid arthritis and lupus, with topline results expected by mid-2025 |
Market Opportunity | Delve into IGM's positioning to capture a share of the $1.5+ billion inflammation and immunology market by 2025 |
Analyst Perspectives | Discover varied analyst views on IGM's future, with price targets ranging from $9 to $48, reflecting both optimism and caution |
Metrics to compare | IGMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIGMSPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −1.2x | −0.5x | |
PEG Ratio | −0.02 | −0.06 | 0.00 | |
Price/Book | 0.8x | 2.3x | 2.6x | |
Price / LTM Sales | 0.5x | 10.1x | 3.3x | |
Upside (Analyst Target) | −12.2% | 292.9% | 42.8% | |
Fair Value Upside | Unlock | 21.2% | 6.5% | Unlock |